Share price · GILD
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when GILD's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 30 Oct 2026+3.1%
- 5 Aug 2026-2.6%
- 4 Aug 2026+3.1%
- 21 Jul 2026-2.2%
- 10 Jul 2026-3.7%
Nothing announced by GILD that day or the session before.
- 7 Jul 2026+5.2%
Nothing announced by GILD that day or the session before.
- 16 Jun 2026+2.4%
- 11 Jun 2026+3.6%
- 9 Jun 2026-2.0%
- 11 Feb 2026+5.8%
Share of unusual movement by asset
For each asset, the share of GILD's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
Assets
(27 total)
| Target & Modality | |||
|---|---|---|---|
Ambrisentan(Letairis) | Approved | Endothelin A receptorSmall molecule | Pulmonary Arterial Hypertension |
Bictegravir(Biktarvy) | Approved | HIV integraseSmall molecule | HIV |
| Approved | HIV integrase · HIV capsidSmall molecule | HIV | |
Elvitegravir(Stribild) | Approved | HIV integraseSmall molecule | HIV |
| Approved | HIV reverse transcriptaseSmall molecule | HIV | |
| Approved | HIV reverse transcriptaseSmall molecule | HIV | |
| Approved | HIV capsidSmall molecule | HIV | |
| Approved | HIV capsidSmall molecule | HIV | |
| Approved | TROP2Antibody–drug conjugate | Non-Small Cell Lung CancerBreast CancerBladder / Urothelial CancerEndometrial Cancer HR+/HER2- Metastatic Breast Cancer, Urothelial Carcinoma | |
Seladelpar(Livdelzi) | Approved | PPAR-deltaSmall molecule | Cholestatic Liver Disease Primary Biliary Cholangitis |
| Approved | HBV polymerase (reverse transcriptase)Small molecule | Chronic Hepatitis B | |
Tenofovir alafenamide/emtricitabine(Descovy) | Approved | HIV reverse transcriptaseSmall molecule | HIV |
| Approved | HIV reverse transcriptase (RT)Small molecule | HIVChronic Hepatitis B | |
| Phase 3 | BCMACell therapy | Multiple Myeloma | |
filgotinib(Jyseleca) | Phase 3 | JAK · JAK1Small molecule | Rheumatoid Arthritis |
Discontinued programmes (1)
Development of these assets stopped. Each page states the sourced discontinuation and keeps the trials as evidence history.
Upcoming events
(40 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2026 (3)
2027 (13)
February 2027 (1)
What to watch
March 2027 (2)
May 2027 (1)
What to watch
June 2027 (2)
August 2027 (2)
September 2027 (1)
What to watch
November 2027 (1)
What to watch
2028 (9)
March 2028 (1)
April 2028 (1)
What to watch
June 2028 (2)
July 2028 (2)
September 2028 (1)
What to watch
November 2028 (1)
What to watch
December 2028 (1)
What to watch
2029 (7)
March 2029 (2)
May 2029 (1)
June 2029 (1)
What to watch
September 2029 (2)
What to watch
What to watch
October 2029 (1)
What to watch
2030 (6)
April 2030 (1)
What to watch
May 2030 (1)
What to watch
July 2030 (1)
What to watch
August 2030 (1)
What to watch
October 2030 (1)
What to watch
November 2030 (1)
What to watch
2039 (1)
March 2039 (1)
What to watch
2042 (1)
February 2042 (1)
What to watch
Regulatory and conference events
(11)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Coming up
Recent
Financial reports
Quarterly & interim (16)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q3 | $8.3B | $1.6B | $6.4B+ $0 short-term inv. | —$5.0B operating cash flow | report ↗ |
View 15 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | $7.8B | $1.8B | $3.2B+ $0 short-term inv. | $10.5B$3.6B operating cash flow | report ↗ |
| 2026-Q1 | $7.0B | $1.4B | $7.6B+ $15M short-term inv. | —$2.5B operating cash flow | report ↗ |
| 2025-Q3 | $7.8B | $1.3B | $7.3B+ $19M short-term inv. | —$4.1B operating cash flow | report ↗ |
| 2025-Q2 | $7.1B | $1.5B | $5.1B+ $69M short-term inv. | —$827M operating cash flow | report ↗ |
| 2025-Q1 | $6.7B | $1.4B | $7.9B | —$1.8B operating cash flow | report ↗ |
| 2024-Q3 | $7.5B | $1.4B | $5.0B+ $0 short-term inv. | —$4.3B operating cash flow | report ↗ |
| 2024-Q2 | $7.0B | $1.4B | $2.8B+ $0 short-term inv. | —$1.3B operating cash flow | report ↗ |
| 2024-Q1 | $6.7B | $1.5B | $4.7B+ $0 short-term inv. | $4.2B$2.2B operating cash flow | report ↗ |
| 2023-Q3 | $7.1B | $1.5B | $5.7B+ $1.2B short-term inv. | —$1.8B operating cash flow | report ↗ |
| 2023-Q2 | $6.6B | $1.4B | $5.7B+ $963M short-term inv. | —$2.3B operating cash flow | report ↗ |
| 2023-Q1 | $6.4B | $1.4B | $4.9B+ $936M short-term inv. | —$1.7B operating cash flow | report ↗ |
| 2022-Q3 | $7.0B | $1.1B | $4.7B+ $961M short-term inv. | —$2.9B operating cash flow | report ↗ |
| 2022-Q2 | $6.3B | $1.1B | $4.7B+ $924M short-term inv. | —$1.8B operating cash flow | report ↗ |
| 2022-Q1 | $6.6B | $1.2B | $4.3B+ $1.0B short-term inv. | —$1.8B operating cash flow | report ↗ |
| 2021-Q3 | $7.4B | $1.1B | $4.4B+ $1.4B short-term inv. | —$3.3B operating cash flow | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | $29.4B | $5.8B | $7.6B+ $68M short-term inv. | —$10.0B operating cash flow | report ↗ |
For full-year 2025, Gilead Sciences reported revenue of $29,443M, up 2.4% YoY, with R&D spend of $5,799M, down 1.8% YoY. The company ended the year with $7,564M in cash and equivalents, or $10,605M including marketable debt securities, and reported net income of $8,510M.
For 2026, Gilead guided to product sales of $29,600M–$30,000M, product sales excluding Veklury of $29,000M–$29,400M, Veklury of $600M, diluted EPS of $6.75–$7.15, and non-GAAP diluted EPS of $8.45–$8.85. Clinically, the company reported positive Phase 3 ARTISTRY-1 and ARTISTRY-2 results for its BIC/LEN HIV regimen, while Trodelvy’s ASCENT-07 study missed its primary endpoint and the Phase 3 STAR-221 study was discontinued. Other updates included a Yescarta label expansion, new data from the iMMagine-1, KITE-753/KITE-363, and ASSURE studies, the U.S. launch of Yeztugo, and a declared quarterly dividend of $0.82 per share.
View 4 more years
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2024-FY | $28.8B | $5.9B | $10.0B+ $0 short-term inv. | —$10.8B operating cash flow | report ↗ |
| 2023-FY | $27.1B | $5.7B | $6.1B+ $1.2B short-term inv. | —$8.0B operating cash flow | report ↗ |
| 2022-FY | $27.3B | $5.0B | $5.4B+ $973M short-term inv. | —$9.1B operating cash flow | report ↗ |
| 2021-FY | $27.3B | $5.4B | $5.3B+ $1.2B short-term inv. | —$11.4B operating cash flow | report ↗ |
Insider transactions
Open-market activity, trailing 12 months: 0 purchases ($0), 88 sales ($108.9M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-11-16 | Dickinson Andrew D · Chief Financial Officer | Open-market sale | 3,000 | $171.47 | $514K | Form 4 |
| 2026-11-16 | Mercier Johanna · Chief Comm & Corp Aff Officer | Option exercise | 25,000 | $72.34 | $1.8M | Form 4 |
| 2026-11-16 | Mercier Johanna · Chief Comm & Corp Aff Officer | Open-market sale | 13,922 | $169.97 | $2.4M | Form 4 |
| 2026-11-16 | Mercier Johanna · Chief Comm & Corp Aff Officer | Open-market sale | 13,178 | $171.09 | $2.3M | Form 4 |
| 2026-11-16 | Mercier Johanna · Chief Comm & Corp Aff Officer | Open-market sale | 900 | $171.69 | $155K | Form 4 |
| 2026-11-16 | Mercier Johanna · Chief Comm & Corp Aff Officer | Option exercise (derivative) | 25,000 | — | — | Form 4 |
| 2026-11-12 | Kramer Kelly A. · director | Option exercise | 10,376 | $66.92 | $694K | Form 4 |
| 2026-11-12 | Kramer Kelly A. · director | Open-market sale | 1,676 | $168.23 | $282K | Form 4 |
Institutional holders
From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 2,293 reporting institutions held 1058.3M shares ($140.2B, 85.3% of shares outstanding).
| # | Institution | Shares | Value |
|---|---|---|---|
| 1 | BlackRock, Inc. | 119,010,973 | $16.6B |
| 2 | VANGUARD CAPITAL MANAGEMENT LLC | 80,654,776 | $11.2B |
| 3 | FMR LLC | 71,906,290 | $10.0B |
| 4 | STATE STREET CORP | 59,858,585 | $8.3B |
| 5 | Capital World Investors | 41,283,933 | $5.8B |
| 6 | VANGUARD PORTFOLIO MANAGEMENT LLC | 35,129,465 | $4.9B |
| 7 | JPMORGAN CHASE & CO | 33,992,410 | $4.6B |
| 8 | GEODE CAPITAL MANAGEMENT, LLC | 29,726,052 | $4.1B |
| 9 | Capital Research Global Investors | 27,127,533 | $3.8B |
| 10 | Dodge & Cox | 24,250,826 | $3.4B |
| 11 | MORGAN STANLEY | 23,299,295 | $3.2B |
| 12 | BANK OF AMERICA CORP /DE/ | 19,978,936 | $2.8B |
| 13 | Invesco Ltd. | 15,526,336 | $2.2B |
| 14 | Bank of New York Mellon Corp | 15,053,151 | $2.1B |
| 15 | NORTHERN TRUST CORP | 13,820,379 | $1.9B |